{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.2","upperLimit":"64.6","value":"54.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"description":"ORR, which includes complete response (CR) and partial response (PR) in the Main cohort as determined by IRC assessment. ORR is the percentage of participants with a best overall disease response of CR or PR, where the best overall disease response is defined as the best disease response recorded from CTL019 infusion until progressive disease or start of new anticancer therapy (including ASCT), whichever comes first.\n\nResponse was assessed according to Evaluation Criteria in diffuse large B cell lymphoma studies (based on Cheson Response criteria and the Lugano Classification (2014))","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): Comprised of all patients in the Main cohort who received infusion of tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Overall Response Rate (ORR) Per Independent Review Committee (IRC) in Main Cohort","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}